DiabetologyNews.net

Diabetology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Neurobase.it

New data from a Phase IV study evaluating Linagliptin ( 5 mg ) as monotherapy and in combination with Metformin ( 1500 or 2000 mg ) in treatment-naive adults with newly diagnosed ( less than 12 months ...


The results from a new pooled analysis of phase III data for the dipeptidyl peptidase-4 ( DPP-4 ) inhibitor Linagliptin ( Trajenta ) were presented at the American Diabetes Association ( ADA ) 73rd Sc ...


The EMA ( European Medicines Agency ) is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis ( inflammation of the pancreas ) and preca ...


The results from a new study in which Linagliptin ( Tradjenta ), a DPP-4 inhibitor, has demonstrated statistically significant reductions in blood glucose levels ( HbA1c ) after 12 weeks ( primary end ...


The results of a 52-week phase III clinical trial of Empagliflozin, presented at the American Diabetes Association ( ADA ) 73rd Scientific Sessions, showed statistically significant reductions in HbA1 ...


The results of a 24-week phase III clinical trial, which showed that treatment with the investigational compound Empagliflozin as monotherapy produced statistically significant reductions in HbA1c ver ...


The results of two phase III 24-week clinical trials of the investigational agent Empagliflozin added to Metformin with and without the addition of sulfonylurea, in people with type 2 diabetes ( T2D ) ...


The results from two phase III clinical studies that showed Linagliptin ( Tradjenta ) in Asian adults, as monotherapy and in combination with Metformin, improved blood glucose control in people with t ...


The results of a 78-week phase III clinical trial of the investigational agent Empagliflozin as add-on to basal Insulin in adults with type 2 diabetes ( T2D ), presented at the American Diabetes Assoc ...


The results from two exploratory analyses assessing the risk of hypoglycemia with Linagliptin ( Tradjenta ) treatment in adults with type 2 diabetes ( T2D ), were presented.In an exploratory analysis ...


The FDA ( Food and Drug Administration ) has approved updates to the full U.S. Prescribing Information ( PI ) for Tradjenta ( Linagliptin ) tablets and Jentadueto ( Linagliptin and Metformin hydrochlo ...


Positive top-line results of two additional phase III AWARD trials for Dulaglutide, an investigational, long-acting glucagon-like peptide 1 ( GLP-1 ) receptor agonist being studied as a once-weekly tr ...


The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medicat ...


The American College of Physicians ( ACP ) has developed a guideline to present the evidence and provide clinical recommendations on the comparative effectiveness and safety of type 2 diabetes medicat ...


Sanofi-Aventis has announced that Lixisenatide ( Lyxumia ) once-daily achieved primary efficacy endpoint and fewer hypoglycemias versus Exenatide ( Byetta ) twice-daily. The GetGoal-X Phase III stu ...